83 Clemenceau Avenue
No. 12-03 UE Square
Singapore 239920
Singapore
65 6222 4235
https://aslanpharma.com
Sector(s):Â Healthcare
Industry:Â Biotechnology
Full Time Employees:Â 27
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. | Founder, CEO & Exec. Director | N/A | N/A | 1973 |
Mr. Kiran Kumar Asarpota | COO & Head of Fin. | N/A | N/A | 1979 |
Mr. Ben Goodger | Gen. Counsel | N/A | N/A | 1963 |
Mr. Stephen Doyle | Chief Bus. Officer | N/A | N/A | 1973 |
Charlie Hsu | Investor Relations Director | N/A | N/A | N/A |
Chi-Chin Wang | IR & Corp. Devel. Director | N/A | N/A | N/A |
Dr. Alexandre Kaoukhov M.D. | Chief Medical Officer | N/A | N/A | 1974 |
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions. It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway. Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
ASLAN Pharmaceuticals Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.